<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hsieh RC</submitter><funding>NCI NIH HHS</funding><pagination>eabl9330</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9373855</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7(72)</volume><pubmed_abstract>Radiotherapy (RT) of colorectal cancer (CRC) can prime adaptive immunity against tumor-associated antigen (TAA)-expressing CRC cells systemically. However, abscopal tumor remissions are extremely rare, and the postirradiation immune escape mechanisms in CRC remain elusive. Here, we found that irradiated CRC cells used ATR-mediated DNA repair signaling pathway to up-regulate both CD47 and PD-L1, which through engagement of SIRPα and PD-1, respectively, prevented phagocytosis by antigen-presenting cells and thereby limited TAA cross-presentation and innate immune activation. This postirradiation CD47 and PD-L1 up-regulation was observed across various human solid tumor cells. Concordantly, rectal cancer patients with poor responses to neoadjuvant RT exhibited significantly elevated postirrad</pubmed_abstract><journal>Science immunology</journal><pubmed_title>ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer.</pubmed_title><pmcid>PMC9373855</pmcid><funding_grant_id>P30 CA016672</funding_grant_id><funding_grant_id>R01 CA231360</funding_grant_id><pubmed_authors>Prasad R</pubmed_authors><pubmed_authors>Kim YSB</pubmed_authors><pubmed_authors>De Azevedo RA</pubmed_authors><pubmed_authors>Jayaprakash P</pubmed_authors><pubmed_authors>Lin SH</pubmed_authors><pubmed_authors>Srinivasamani A</pubmed_authors><pubmed_authors>Chou YC</pubmed_authors><pubmed_authors>Boda AR</pubmed_authors><pubmed_authors>Rudqvist NP</pubmed_authors><pubmed_authors>Bhanu KR</pubmed_authors><pubmed_authors>Venkatesulu BP</pubmed_authors><pubmed_authors>DePinho RA</pubmed_authors><pubmed_authors>Hsieh RC</pubmed_authors><pubmed_authors>Morrow B</pubmed_authors><pubmed_authors>Taniguchi C</pubmed_authors><pubmed_authors>Hsu WH</pubmed_authors><pubmed_authors>Slay R</pubmed_authors><pubmed_authors>Chen J</pubmed_authors><pubmed_authors>Chan LC</pubmed_authors><pubmed_authors>Hartley G</pubmed_authors><pubmed_authors>Vilar E</pubmed_authors><pubmed_authors>Wu RC</pubmed_authors><pubmed_authors>Chen CH</pubmed_authors><pubmed_authors>Krishnan S</pubmed_authors><pubmed_authors>Gubin M</pubmed_authors><pubmed_authors>Hegde SM</pubmed_authors><pubmed_authors>Winkler M</pubmed_authors><pubmed_authors>Hung MC</pubmed_authors><pubmed_authors>Lea ST</pubmed_authors><pubmed_authors>Liu A</pubmed_authors><pubmed_authors>Steiner M</pubmed_authors><pubmed_authors>Couillault CA</pubmed_authors><pubmed_authors>Wang CC</pubmed_authors><pubmed_authors>Curran MA</pubmed_authors></additional><is_claimable>false</is_claimable><name>ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer.</name><description>Radiotherapy (RT) of colorectal cancer (CRC) can prime adaptive immunity against tumor-associated antigen (TAA)-expressing CRC cells systemically. However, abscopal tumor remissions are extremely rare, and the postirradiation immune escape mechanisms in CRC remain elusive. Here, we found that irradiated CRC cells used ATR-mediated DNA repair signaling pathway to up-regulate both CD47 and PD-L1, which through engagement of SIRPα and PD-1, respectively, prevented phagocytosis by antigen-presenting cells and thereby limited TAA cross-presentation and innate immune activation. This postirradiation CD47 and PD-L1 up-regulation was observed across various human solid tumor cells. Concordantly, rectal cancer patients with poor responses to neoadjuvant RT exhibited significantly elevated postirrad</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jun</publication><modification>2025-04-21T22:26:37.998Z</modification><creation>2025-04-05T18:45:15.584Z</creation></dates><accession>S-EPMC9373855</accession><cross_references><pubmed>35687697</pubmed><doi>10.1126/sciimmunol.abl9330</doi></cross_references></HashMap>